Immunotherapy with or without a gut bacteria pill for kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced or metastatic kidney cancer with a clear cell component
- You have not had prior immunotherapy (like PD-1 or CTLA-4 inhibitors) or any systemic treatment for advanced kidney cancer (except if the prior therapy was after surgery and your cancer returned at least 6 months later)
- You have at least one tumor that can be measured on scans
- Your blood counts, liver, and kidney function are within acceptable ranges
- You can take oral medications and do not need a feeding tube
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Hear when a new Advanced Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.